Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Long-term cohort studies

Topic: Amyloid, tau and blood-test diagnosis

Improved prediction of progression to Alzheimer's Disease (AD) among older individuals with mild cognitive impairment (MCI) is of high clinical and societal importance. We recently developed a polygenic hazard score (PHS) that predicted age of AD onset above and beyond APOE . Here, we used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to further explore the potential clinical utility of PHS for predicting AD development in older adults with MCI.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kauppi, K., Fan, C. C., McEvoy, L. K., Holland, D., Tan, C. H., Chen, C. H., et al. (2018). Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease. Frontiers in neuroscience. https://doi.org/10.3389/fnins.2018.00260

Vancouver

Kauppi K, Fan CC, McEvoy LK, Holland D, Tan CH, Chen CH, et al. Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease. Frontiers in neuroscience. 2018. doi:10.3389/fnins.2018.00260. PMID: 29760643.

BibTeX

@article{kauppi2018-29760643,
  author  = {Kauppi, K. and Fan, C. C. and McEvoy, L. K. and Holland, D. and Tan, C. H. and Chen, C. H. and Andreassen, O. A. and Desikan, R. S. and others},
  title   = {{Combining Polygenic Hazard Score With Volumetric MRI and Cognitive Measures Improves Prediction of Progression From Mild Cognitive Impairment to Alzheimer's Disease}},
  journal = {Frontiers in neuroscience},
  year    = {2018},
  doi     = {10.3389/fnins.2018.00260},
  pmid    = {29760643},
  url     = {https://doi.org/10.3389/fnins.2018.00260}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

A polygenic hazard score, alone and combined with MRI and cognitive measures, was used to predict progression from mild cognitive impairment to Alzheimer's disease. This suggests such combined measures may help identify which people with mild cognitive impairment are more likely to develop Alzheimer's disease.

Study details

How this study scored 44/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 42 of the 96 points it could be judged on, which is 44 of 100. Total 44 of 100.42 of the 96 points we could judge = 44 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 42 of the 96 points we could judge it on, which is 44 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in neuroscience)
Journal's citation record 2 / 4 Frontiers in Neuroscience: journal h-index 226 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 60 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 6.0 citations a year over 10 year(s) since 2018
Impact for its field and year 3 / 6 Cited 4.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 1 / 4 Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of California, San Francisco: institution h-index 1,915 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 5 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29760643)
Free to read 2 / 2 Free to read
Points 42 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 42 of the 96 points we could judge it on is 44 out of 100.
Total 44 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Long-term cohort studies

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →